BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to provide a summary of current operating initiatives including the integration and disposition of assets acquired in ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces a proposed consolidation of the ...

The company’s lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large ...

The Connecticut Sun is excited to announce a new multi-year relationship with TD Bank to become the exclusive financial services sponsor for the WNBA team. This collaboration is designed to engage Sun ...

LADENBURG, Germany I May 27, 2025 I Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), ...

Religious services, concerts and vigils are scheduled to mark the fifth anniversary of George Floyd’s murder by a police ...

Chinese Premier Li Qiang has met with Indonesia’s President Prabowo Subianto to discuss ways to expand trade and investment ...

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from ...

That’s what The Leukemia & Lymphoma Society (LLS) offers through Light The Night, a powerful community event series that ...

When facing a lymphoma diagnosis, understanding the available treatment options becomes crucial for patients navigating this challenging journey. Lymphoma, a cancer affecting the immune system’s ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...